H.C. Wainwright analyst Swayampakula Ramakanth downgraded Surface Oncology (SURF) to Neutral from Buy with a $5 price target after the company announced that it has entered into an agreement to merge with Coherus BioSciences (CHRS) and be acquired in a stock-for-stock transaction for up to $65M.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SURF:
